Asons Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 13-12-2024
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.03 Cr
as on 13-12-2024
- Revenue 550.52%
(FY 2023)
- Profit 31963.37%
(FY 2023)
- Ebitda 607.60%
(FY 2023)
- Net Worth 30513.13%
(FY 2023)
- Total Assets 111.36%
(FY 2023)
About Asons Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹11.03 Cr.
Jigneshkumar Shah and Devangiben Shah serve as directors at the Company.
- CIN/LLPIN
U24304GJ2021PTC125300
- Company No.
125300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Asons Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jigneshkumar Shah  | Director | 02-Sep-2021 | Current |
| Devangiben Shah | Director | 02-Sep-2021 | Current |
Financial Performance of Asons Pharmaceuticals.
Asons Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 550.52% increase. The company also saw a substantial improvement in profitability, with a 31963.37% increase in profit. The company's net worth Soared by an impressive increase of 30513.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asons Pharmaceuticals?
Unlock access to Asons Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Purecaps India Private LimitedActive 3 years 3 monthsJigneshkumar Shah and Devangiben Shah are mutual person
- Asons Biotech Private LimitedActive 1 year 7 months
Jigneshkumar Shah and Devangiben Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Mar 2022 | ₹2.94 Cr | Open |
Others Creation Date: 31 Dec 2021 | ₹8.09 Cr | Open |
How Many Employees Work at Asons Pharmaceuticals?
Asons Pharmaceuticals has a workforce of 10 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asons Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asons Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
